[Successful treatment with preceding low-intensity chemotherapy in a primary mediastinal large B cell lymphoma patient diagnosed at 11 weeks of pregnancy]

Rinsho Ketsueki. 2019;60(2):112-117. doi: 10.11406/rinketsu.60.112.
[Article in Japanese]

Abstract

At 11 weeks of pregnancy, a 31-year-old woman presented with an anterior chest tumor and dyspnea. A computed tomography (CT) scan revealed a bulky tumor in the mediastinum that compressed the trachea. She underwent a CT-guided needle biopsy and was diagnosed with primary mediastinal large B cell lymphoma. She was initially treated with steroid pulse therapy, followed by vincristine-cyclophosphamide-prednisolone (VCP) therapy, which relieved her dyspnea. She was then treated with 8 cycles of rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP) therapy at 13 weeks of pregnancy. The patient delivered her baby at 35 weeks and 6 days of pregnancy. Despite the preterm delivery and other than the low-birth weight, her baby was healthy. A positron emission tomography-CT scan showed that a complete metabolic response was achieved. Our case report suggests that steroid pulse and VCP therapy followed by R-CHOP therapy is safe and effective for patients with malignant lymphoma in their first trimester of pregnancy.

Keywords: First trimester; Low-intensity chemotherapy; Pregnancy; Primary mediastinal large B cell lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Prednisone / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Rituximab
  • Steroids / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Steroids
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone